Ansell (ASX:ANN): Safety Solutions Growth, Margin Expansion and Tariff Management in Focus

Sonal Goyal

09 September 2026 10:48 PM AEST

Ansell (ASX:ANN): Safety Solutions Growth, Margin Expansion and Tariff Management in Focus

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Ansell shares were priced at A$42.00 on 9 September 2026.
The group is exposed to both healthcare and industrial Demand through a global personal-protection portfolio.
FY26 Earnings growth was supported by pricing, product mix, sourcing actions and productivity improvements.
Investors may focus on FY27 execution across strategic markets, ERP upgrades, tariffs and Margin discipline.

Ansell (ASX:ANN) occupies a distinctive position within healthcare because its earnings are linked to both medical demand and industrial safety spending. The company supplies protective products across healthcare, life sciences, Manufacturing and other workplaces, giving investors exposure to a diversified safety-solutions model. Ansell shares were priced at A$42.00 on 9 September 2026.

Business Mix Matters

The portfolio spans exam and single-use gloves, surgical products, cleanroom protection, mechanical hand protection and chemical-protection solutions. Healthcare accounted for the larger share of segment sales in FY26, while industrial remained an important earnings contributor. Demand can therefore be shaped by hospital activity, life-sciences production, manufacturing trends and workplace safety requirements.

FY26 Earnings Context

Ansell reported FY26 sales of US$2.14 billion and adjusted EBIT of US$321.9 million, with adjusted EPS of US148.6 cents. Management said sales growth accelerated in the second half and that margin improvement reflected a greater contribution from higher-value markets, sourcing actions, price increases and productivity gains. Operating Cash Flow also improved materially, supporting balance-sheet flexibility and ongoing Capital returns.

Healthcare Growth Drivers

Within Healthcare, cleanroom products were a notable growth area, supported by demand from pharmaceutical, medical-device and semiconductor customers. Surgical and exam/single-use products also contributed. For investors, the key issue is whether Ansell can keep shifting its mix toward differentiated products and end markets where performance, compliance and reliability support better economics.

Tariffs and Cost Control

Ansell’s recent performance highlights the importance of pricing and sourcing discipline. The company used supply-chain optimisation and price increases to offset higher US tariffs and cost Inflation linked to the Middle East crisis. These pressures remain relevant because protective-equipment businesses are sensitive to input costs, freight and customer willingness to absorb price changes.

Productivity and Capital Allocation

The Accelerated Productivity Investment Program has reached its recurring pre-tax savings target, and attention is moving to the IT phase, including planned ERP upgrades beginning in North America in FY27. Ansell is also continuing its on-market share buyback. These initiatives combine cost simplification with capital allocation but require disciplined implementation.

Risks to Consider

Execution remains central to the investment case. Risks include changes in Tariff settings, supply-chain disruption, geopolitical cost pressure, weaker industrial demand, customer inventory movements and implementation risk around technology and operational changes. Ansell also competes across global healthcare and industrial markets where pricing, innovation, product quality and distributor relationships influence customer retention and margins.

What Investors May Watch Next

For FY27, Ansell expects adjusted EPS of US158 cents to US170 cents and anticipates constant-currency sales growth from a combination of higher volumes and pricing actions already implemented. Management is prioritising the US, scientific markets and selected industrial verticals while pursuing commercial and operational excellence. Progress against those priorities, together with cash conversion and margin performance, should remain central to how investors assess the shares.

Conclusion

Ansell’s investment story combines healthcare exposure, industrial safety demand, global manufacturing and a growing emphasis on higher-value protection solutions. The company enters FY27 with improved earnings, stronger cash generation and defined productivity initiatives, but also with external pressures from tariffs, costs and macroeconomic uncertainty. For shareholders, the next phase will be shaped by whether Ansell can convert strategic-market growth and operational simplification into sustained earnings quality.

FAQs

Q: What does Ansell do?

A:Ansell manufactures personal-protection products for healthcare and industrial workplaces, including gloves, cleanroom products and chemical and mechanical protection solutions.

Q: What exchange does Ansell trade on?

A:Ansell trades on the Australian Securities Exchange under the ticker (ASX:ANN).

Q: What was Ansell’s share price on 9 September 2026?

A:Ansell shares were priced at A$42.00 on 9 September 2026.

Q: What are investors watching in FY27?

A:Key areas include sales growth in strategic markets, margin performance, ERP implementation, tariff management, cash generation and execution of operational initiatives.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.